Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Selective Serotonin Reuptake Inhibitor Toxicity Differential Diagnoses

  • Author: Tracy A Cushing, MD, MPH, FACEP, FAWM; Chief Editor: Asim Tarabar, MD  more...
 
Updated: Oct 21, 2015
 
 

Diagnostic Considerations

Other conditions to be considered include the following:

  • Malignant hyperthermia
  • Delirium tremens
  • Anticholinergic toxicity
  • Antidepressant toxicity
  • Antihistamine toxicity
  • Carbamazepine toxicity
  • Cocaine toxicity
  • MDMA toxicity
  • Methamphetamine toxicity
  • MAOI toxicity
  • Neuroleptic agent toxicity
  • Phencyclidine toxicity
  • Sympathomimetic toxicity

Differential Diagnoses

 
 
Contributor Information and Disclosures
Author

Tracy A Cushing, MD, MPH, FACEP, FAWM Assistant Professor and Attending Physician, Department of Emergency Medicine, University of Colorado School of Medicine

Tracy A Cushing, MD, MPH, FACEP, FAWM is a member of the following medical societies: American College of Emergency Physicians, Society for Academic Emergency Medicine, Wilderness Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Theodore I Benzer, MD, PhD Assistant Professor in Medicine, Harvard Medical School; Director of the ED Observation Unit, Director of Toxicology, Chair of Quality and Safety, Department of Emergency Medicine, Massachusetts General Hospital

Theodore I Benzer, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians

Disclosure: Nothing to disclose.

Monica Noori, MD Resident Physician, Department of Emergency Medicine, Denver Health

Monica Noori, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Emergency Medicine Residents' Association

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Howard Kim, MD Resident Physician, Department of Emergency Medicine, Denver Health Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

John G Benitez, MD, MPH Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

John G Benitez, MD, MPH is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Miguel C Fernandez, MD, FAAEM, FACEP, FACMT, FACCT Associate Clinical Professor, Department of Surgery/Emergency Medicine and Toxicology, University of Texas School of Medicine at San Antonio; Medical and Managing Director, South Texas Poison Center

Miguel C Fernandez, MD, FAAEM, FACEP, FACMT, FACCT is a member of the following medical societies: American Academy of Emergency Medicine, American College of Clinical Toxicologists, American College of Emergency Physicians, American College of Medical Toxicology, American College of Occupational and Environmental Medicine, Society for Academic Emergency Medicine, and Texas Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991 Jun. 148(6):705-13. [Medline].

  2. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17. 352(11):1112-20. [Medline].

  3. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002 Jan 9. 287(2):203-9. [Medline].

  4. Pirraglia PA, Stafford RS, Singer DE. Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care. Prim Care Companion J Clin Psychiatry. 2003 Aug. 5(4):153-157. [Medline]. [Full Text].

  5. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006 Jun 1. 42(11):1578-83. [Medline].

  6. Kaplan H, Sadock B. Serotonin-specific reuptake inhibitors. Synopsis of Psychiatry. 8th ed. Williams and Wilkins; 1988. 1083-92.

  7. Hirsch M, Birnbaum R. Pharmacology of Antidepressants. UpToDate [serial online]. 2004. v 11.3.:

  8. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. 1997 Jun. 17(3):208-21. [Medline].

  9. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol. 2008 Jan. 23 Suppl 1:43-51. [Medline].

  10. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999. 13(1):100-9. [Medline].

  11. Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ. 2003 May 27. 168(11):1439-42. [Medline].

  12. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med. 2003 Mar. 4(1):63-74. [Medline].

  13. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000 Jul. 79(4):201-9. [Medline].

  14. White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol. 2008 Dec. 4(4):238-50. [Medline]. [Full Text].

  15. Klein-Schwartz W, Benson BE, Lee SC, Litovitz T. Comparison of citalopram and other selective serotonin reuptake inhibitor ingestions in children. Clin Toxicol (Phila). 2012 Jun. 50(5):418-23. [Medline].

  16. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004. 42(3):277-85. [Medline].

  17. US Food and Drug Administration. Celexa (citalopram hydrobromide): Drug Safety Communication – Abnormal Heart Rhythms Associated With High Doses. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm269481.htm. Accessed: August 24, 2011.

  18. Celexa (citalopram hydrobromide) [package insert]. St. Louis, Missouri: Forest Pharmaceuticals, Inc. August, 2011. Available at [Full Text].

  19. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009 Jun. 104(6):1475-82. [Medline].

  20. Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M. 2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st Annual Report. Clin Toxicol (Phila). 2014 Dec. 52 (10):1032-283. [Medline].

  21. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003 Sep. 96(9):635-42. [Medline].

  22. Chechani V. Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Crit Care Med. 2002 Feb. 30(2):473-6. [Medline].

  23. [Guideline] Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007 May. 45(4):315-32. [Medline].

  24. Evans CE, Sebastian J. Serotonin syndrome. Emerg Med J. 2007 Apr. 24(4):e20. [Medline]. [Full Text].

  25. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998 Jul-Aug. 16(4):615-9. [Medline].

  26. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999. 13(1):100-9. [Medline].

  27. Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001 Jan 26. 890(1):23-31. [Medline].

  28. Nisijima K, Yoshino T, Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology (Berl). 2000 May. 150(1):9-14. [Medline].

  29. Marx J, Hockberger R, Walls R. Rosen's Emergency Medicine. 5th ed. CV Mosby; 2002. 2087-2103.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.